Effect of Duration of Feminizing Hormone Therapy on Facial Fat Volumes (Q28127)
Jump to navigation
Jump to search
No description defined
- Effect of Duration of Feminizing Hormone Therapy on Facial Fat Volumes.
Language | Label | Description | Also known as |
---|---|---|---|
English | Effect of Duration of Feminizing Hormone Therapy on Facial Fat Volumes |
No description defined |
|
Statements
Gender-affirming feminizing hormone therapy induces body fat redistribution. (English)
BACKGROUND (English)
Copyright © 2023 by the American Society of Plastic Surgeons. (English)
2023
However, the amount and timing of facial fat changes in response to feminizing hormone therapy are unknown, despite being relevant to counseling and surgical planning for facial gender-affirming surgery. (English)
BACKGROUND (English)
Copyright © 2023 by the American Society of Plastic Surgeons. (English)
2023
The authors assessed the influence of feminizing hormone therapy duration on malar and temporal fat volume. (English)
BACKGROUND (English)
Copyright © 2023 by the American Society of Plastic Surgeons. (English)
2023
Malar and temporal fat volumes were compared using computed tomography in transfeminine patients (age, 20 to 29 years; body mass index, 18.5 to 24.9) treated with feminizing hormone therapy for less than 2 years versus 2 years or longer. (English)
METHODS (English)
Copyright © 2023 by the American Society of Plastic Surgeons. (English)
2023
Patients with previous surgical or nonsurgical facial soft-tissue interventions were excluded. (English)
METHODS (English)
Copyright © 2023 by the American Society of Plastic Surgeons. (English)
2023
Multivariable linear regressions evaluated the contribution of hormone therapy duration to malar and temporal fat volumes. (English)
METHODS (English)
Copyright © 2023 by the American Society of Plastic Surgeons. (English)
2023
A total of 45 patients were included, 30 (66.7%) treated with feminizing hormone therapy for 2 years or longer and 15 (33.3%) treated for less than 2 years (median [interquartile range], 44.5 [33.5 to 65.6] versus 15.0 [11.0 to 18.0] months; P < 0.001). (English)
RESULTS (English)
Copyright © 2023 by the American Society of Plastic Surgeons. (English)
2023
Patients treated with hormone therapy for 2 years or longer demonstrated a 1.6-fold greater malar fat volume (5.5 [4.2 to 6.3] versus 3.4 [2.3 to 4.2] cm 3 ; P < 0.001) and 1.4-fold greater temporal fat volume (2.8 [2.4 to 3.6] cm 3 versus 2.0 [1.7 to 2.4] cm 3 ; P = 0.01) compared with those treated for less than 2 years. (English)
RESULTS (English)
Copyright © 2023 by the American Society of Plastic Surgeons. (English)
2023
When accounting for other contributory variables, such as body mass index, skull size, and total soft-tissue depth, in multivariable linear regression models, hormone therapy duration of 2 years or longer independently predicted higher malar (β = 0.51, P < 0.001) and temporal (β = 0.32, P = 0.02) fat volumes. (English)
RESULTS (English)
Copyright © 2023 by the American Society of Plastic Surgeons. (English)
2023
Feminizing hormone therapy increases malar and temporal fat volumes by approximately 2 cm 3 and 0.8 cm 3 for each area, respectively, after 2 years of treatment. (English)
CONCLUSION (English)
Copyright © 2023 by the American Society of Plastic Surgeons. (English)
2023
Therapeutic, III. (English)
CLINICAL QUESTION/LEVEL OF EVIDENCE (English)
Copyright © 2023 by the American Society of Plastic Surgeons. (English)
2023
Shahrzad (English)
Moghadam (English)
S
Yvonne (English)
Roca (English)
Y
Jonnby S (English)
LaGuardia (English)
JS
Kelly X (English)
Huang (English)
KX
Madeline G (English)
Chin (English)
MG
Meiwand (English)
Bedar (English)
M
Sarah K (English)
Fadich (English)
SK
Justine C (English)
Lee (English)
JC
1 November 2024
31 October 2024